Results From The Florida High School State Championships FHSAA - FloWrestling
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial - The Lancet Respiratory Medicine
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID- 19: a retrospective cohort study using electronic health records - The Lancet Psychiatry
COVID-19 - Wikipedia
Nearly 68 million U.S. adults expected to wager on Super Bowl | WWMT
Microorganisms | Free Full-Text | Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development | ACS Central Science
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Detection and quantification of infectious severe acute respiratory coronavirus-2 in diverse clinical and environmental samples | Scientific Reports
47,XYY syndrome: MedlinePlus Genetics
Myths vs. Facts: Making Sense of COVID-19 Vaccine Misinformation | The Brink | Boston University
Animal models for COVID-19: advances, gaps and perspectives | Signal Transduction and Targeted Therapy
Amazon.com: Lenovo Legion 5 Gaming Laptop, 15.6" FHD Display, AMD Ryzen 7 5800H, 16GB RAM, 512GB Storage, NVIDIA GeForce RTX 3050Ti, Windows 10H, Phantom Blue : Electronics
Research progress of different components of PM2.5 and ischemic stroke | Scientific Reports
Two Years into the COVID-19 Pandemic: Lessons Learned | ACS Infectious Diseases
Frontiers | Going viral: A science communication collaboration in the era of COVID-19 and social media
Emerging Telemedicine Tools for Remote COVID-19 Diagnosis, Monitoring, and Management | ACS Nano
Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 - The Lancet
Are You a Novid—Someone Who's Never Had COVID? Science Has Some Clues Why | BU Today | Boston University
An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease | Nature Immunology
